Teleflex’s subsidiary NeoTract has reported positive outcomes from an independent analysis of its UroLift System in UK patients with benign prostatic hyperplasia (BPH).

Conducted by Imperial College Health Partners, the study compared costs and patient outcomes between UroLift and the current standard of care, transurethral resection of the prostate (TURP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Data revealed significant quality of life benefits with the UroLift System. It was further found that replacing TURP with UroLift can save around £27m in post-surgical complication costs for the National Health Service (NHS).

Unlike TURP, which requires hospitalisation of 2.7 days on average, UroLift System does not require overnight hospitalisation, general anaesthesia or post-operative catheterisation.

NHS Trust Leeds Teaching Hospitals urology consultant Oliver Kayes said: “The data analysis from this study sheds new light on the potential cost savings and improved patient outcomes associated with the prostatic urethral lift treatment.

“The UroLift System offers men a new minimally invasive option that reduces the occurrence of these unpleasant side-effects.”

“Post-surgery complications including urinary tract infections and blood transfusions are expensive complications of TURP and burdensome to men. The UroLift System offers men a new minimally invasive option that reduces the occurrence of these unpleasant side-effects.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

UroLift System is designed for the treatment of lower urinary tract symptoms caused due to BPH.

The system requires a minimally invasive transurethral outpatient procedure, during which patients receive permanent implants to alleviate prostate obstruction and directly open the urethra.

Teleflex Interventional Urology business unit president Dave Amerson said: “We are pleased to see this independent analysis highlighting the economic benefits to the NHS and improved quality of life British men may experience with the UroLift System treatment.”

Currently, the UroLift System is available in the US, Australia, Europe, South Korea, Mexico and Canada.